Author: admin

  • Earth is accumulating more heat than scientists predicted — the rate has doubled in 20 years • Mezha.Media

    Earth is accumulating more heat than scientists predicted — the rate has doubled in 20 years • Mezha.Media

    The Earth’s atmosphere is now trapping far more heat than climate models predicted. This energy imbalance has doubled since 2005, from 0.6 to 1.3 watts per square meter, according to researchers from Australia, France and Sweden. The Conversation reports.

    Scientists believe the acceleration is due to the accumulation of greenhouse gases and changes in cloud cover. In particular, the area of white reflective clouds has decreased, while darker ones have increased. This weakens the planet’s ability to reflect the sun’s heat back into space.

    Most of the additional energy (up to 90%) is absorbed by the oceans, but there is also melting of glaciers and warming of land. This accumulation of heat has already raised the average temperature of the Earth by 1.3–1.5°C compared to the pre-industrial period.

    The authors emphasize that real changes are happening faster than the models predict. If the trend continues, the world could face increased heat waves, droughts and storms. What is particularly worrying is that only models with high sensitivity to emissions come close to the recorded values – they predict more severe warming in the future.

    An additional threat is a possible reduction in funding for satellite climate monitoring in the United States, a key tool that allows us to capture such changes at an early stage.

    Share:

    Посилання скопійовано

    Continue Reading

  • Gedatolisib Displays Early Efficacy in mCRPC and Pretreated HER2+ Breast Cancer

    Gedatolisib Displays Early Efficacy in mCRPC and Pretreated HER2+ Breast Cancer

    Image Credit: © Axel Kock – stock.adobe.com

    Treatment with the pan-PI3K and mTORC1/2 inhibitor gedatolisib (PF-05212384) generated clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and patients with metastatic HER2-positive breast cancer, according to data from 2 separate clinical trials evaluating the agent.1

    Findings from the phase 1 portion of a phase 1/2 trial (NCT06190899) showed that patients with mCRPC (n = 36) treated with darolutamide (Nubeqa) in combination with gedatolisib at 120 mg (cohort 1) or 180 mg (cohort 2) experienced a 6-month radiographic progression-free survival (rPFS) rate of 66%. In this study, treatment-related adverse effects (TRAEs) did not lead to treatment discontinuation in any patients, and no patients required dose reductions of either agent due to TRAEs. No instances of grade 3 hyperglycemia were reported, and patients experienced grade 2/3 stomatitis at a rate of 10.5%.

    “We are very encouraged by this preliminary efficacy and safety data,” Igor Gorbatchevsky, MD, chief medical officer of Celcuity, stated in a news release “The 66% 6-month rPFS rate for this novel combination therapy compares favorably to published data for androgen receptor inhibitors in this setting. With no treatment-related discontinuations and less than 3% of patients experiencing grade 3 stomatitis, we believe it is important to explore additional dose options for gedatolisib. Available gedatolisib pharmacokinetic data from other clinical trials in solid tumors suggests a relationship between efficacy and dose levels. Since this preliminary data indicates that the optimal gedatolisib dose for patients with mCRPC may not yet have been reached, the company amended the clinical trial protocol to enable exploration of additional doses in the phase 1/1b portion of this clinical trial to determine the recommended phase 2 dose.”

    In a phase 2 study (NCT03698383), patients with pretreated, metastatic HER2-positive breast cancer harboring PIK3CA mutations (n = 44) administered the combination of gedatolisib and trastuzumab-pkrb (Herzuma) experienced an overall response rate (ORR) of 43% and a median PFS of 6.0 months (95% CI, 5.0-7.7). The median overall survival (OS) was 24.7 months (95% CI, 17.3-not applicable). Grade 3 hyperglycemia occurred in 1 patient (2.3%), and no patients discontinued gedatolisib due to TRAEs.

    “The 43% ORR reported in patients who received at least 3 prior lines of anti-HER2 treatment for their disease is very encouraging and compares favorably to published data for other available therapies in this group of patients,” Gorbatchevsky stated. “The regimen was well tolerated, and no patients discontinued gedatolisib due to treatment-related AEs. While additional clinical studies are needed, this data suggests gedatolisib in combination with HER2 targeted therapy may be an effective and well tolerated therapeutic option for patients with HER2-positive metastatic breast cancer.”

    mCRPC Trial Background

    The phase 1/2 study is enrolling patients at least 18 years of age with histologically or cytologically confirmed adenocarcinoma of the prostate without a small cell component that is comprised of less than 10% neuroendocrine-type cells.2 Patients need to have progressive mCRPC with prior treatment with a next-generation androgen receptor signaling inhibitor in the metastatic setting. An ECOG performance status of 0 or 1, along with adequate bone marrow, hepatic, renal and coagulation function, is also required.

    In phase 1, patients are receiving gedatolisib at 120 mg or 180 mg once per week for 3 weeks on and 1 week off in combination with darolutamide at 600 mg per day in 28-day cycles. Phase 2 will evaluate the recommended dose of gedatolisib in combination with the same darolutamide regimen. Safety and determining the recommended phase 2 dose are the primary end points of phase 1. The primary end point of phase 2 is rPFS.

    HER2-Positive Breast Cancer Trial Info

    This phase 2 study enrolled patients at least 19 years of age with histologically or cytologically confirmed diagnosis of HER2-positive breast cancer with suspected PI3K pathway dependence.3 At least 2 HER-2 directed therapies, including trastuzumab (Herceptin) in the metastatic setting, was required. Patients also needed to have at least 1 measurable lesion per RECIST 1.1 criteria, an ECOG performance status of 0 to 1, and adequate bone marrow and organ function.

    All enrolled patients received trastuzumab-pkrb at 6 mg/kg on day 1 of each 21-day cycle following a loading dose of 8mg/kg in cycle 1 in combination with gedatolisib at 180 mg on days 1, 8, and 15 of every 21-day cycle.

    ORR was the trial’s primary end point. Secondary end points included PFS and OS.

    References

    1. Celcuity reports clinical data from two early phase studies of gedatolisib. News release. Celcuity. June 30, 2025. Accessed June 30, 2025. https://ir.celcuity.com/press-releases/?qmodStoryID=5588407709789214
    2. Gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer. ClinicalTrials.gov. Updated March 21, 2025. Accessed June 30, 2025. https://clinicaltrials.gov/study/NCT06190899
    3. Phase II study of Herzuma plus gedatolisib in patients with HER-2 positive metastatic breast cancer. ClinicalTrials.gov. Updated February 18, 2021. Accessed June 30, 2025. https://clinicaltrials.gov/study/NCT03698383

    Continue Reading

  • Study shows the evolution of biomass over 500 million years

    Study shows the evolution of biomass over 500 million years

    Ecosystems aren’t just defined by what species exist, but by how much life they contain. While scientists understand species diversity and where marine life is most abundant today, we still lack a clear picture of how biomass, the total weight of living organisms, has changed over time.

    Biomass reveals the real impact and energy flow of life in an ecosystem, like knowing not just the cast of a play, but who the lead actors are and how powerful their performances can be. It’s a vital clue to understanding an ecosystem’s true strength and health across deep time.

    While scientists have long known that biodiversity has increased throughout Earth’s history, a new Stanford study adds a key piece: biomass, or the total amount of ocean life, has also mostly grown over the last 500 million years.

    Despite some dips during mass extinction events, the overall trend is upward, just like biodiversity. This suggests a powerful link: as life became more diverse, it also became more abundant, filling the oceans with both variety and volume.

    Scientists uncover massive, diverse ecosystem deep beneath Earth’s surface

    Imagine if ancient seas left behind a diary, not in words, but in shells and skeletons. That’s exactly what the team is decoding. Researchers studied thousands of rock samples packed with the fossilized remains of marine organisms, shells, algae, and tiny protists. These fossils recorded the biomass of their time, that is, the total “living material” preserved across Earth’s history.

    Why does it matter?

    Biomass reveals how much life an ecosystem could support, and how much energy it moves around, making it a key sign of past ocean health.

    Although it once seemed too complex to measure across deep time, researchers took on the challenge. They analyzed over 7,700 limestone samples spanning 540 million years, using a method called petrographic point-counting to examine the amount of fossilized shell material.

    By combining decades of studies with new data, they created a clearer picture of how life in Earth’s oceans has ebbed and flowed through deep history.

    Some sea life could face extinction over the next century

    They found that in the Cambrian Period, fewer than 10% of rocks had shell material. As life diversified during the Ordovician, that percentage rose, evidence of the Cambrian Explosion.

    Calcifying sponges were among the early biomass leaders but were soon overtaken by echinoderms (like early starfish) and marine arthropods (like trilobites and crab ancestors).

    Over the past 230 million years, oceans saw dramatic rises and falls in life, recorded in the shell content of marine rocks. Shell material stayed above 20%, signaling healthy ocean life, until the Late Devonian extinction (~375–360 million years ago) caused a notable drop.

    Then came the worst: the Great Dying (~250 million years ago), the Permian-Triassic extinction, when shell content plunged to just 3%, reflecting a massive collapse in marine life.

    Even after major extinctions like the end-Triassic and the one that ended the dinosaurs, marine life bounced back. In today’s era, the Cenozoic, shell remains now make up over 40% of marine rocks, largely due to mollusks and corals thriving.

    To be sure, this rise reflected real increases in ocean life, not just fewer shell-destroying predators or sampling bias, researchers ran thorough tests. They analyzed fossil samples across shallow and deep waters, various latitudes, and different ancient continental setups.

    Animal poop helps ecosystems adapt to climate change, study

    The result? The trend held strong across the board, showing that the growth in shell content truly reflects a long-term rise in ocean biomass.

    As ocean organisms became more specialized, they got better at using energy and nutrients, boosting ecosystem productivity. This efficient recycling from phytoplankton to decomposers helped support more life, reflected in greater biomass.

    But today, human impacts like pollution, overfishing, and climate change threaten that balance. Scientists warn we may be entering a sixth mass extinction, where shrinking biodiversity could reduce biomass, and future fossil records might carry the traces of this decline.

    Jonathan Payne, Dorrell William Kirby Professor of Earth and Planetary Sciences, said, “Our findings show that overall biomass is linked to biodiversity and that losses in biodiversity may suppress productivity for geologically meaningful intervals, adding one more argument for why conserving biodiversity is essential for the health of humans and our planet.”

    Journal Reference:

    1. Pulkit Singh, Jordan Ferré, Bridget Thrasher, et al. Macroevolutionary coupling of marine biomass and biodiversity across the Phanerozoic. Current Biology. DOI: 10.1016/j.cub.2025.06.006

    Continue Reading

  • WTC Final sets new live broadcast and digital records  | ICC World Test Championship Final, 2025

    WTC Final sets new live broadcast and digital records  | ICC World Test Championship Final, 2025

    Jay Shah, Chairman of the ICC, reflected that these encouraging numbers were a testament to the continued popularity of the most traditional format of the game.

    “The remarkable viewership numbers for the ICC World Test Championship Final, across both broadcast and digital platforms, are a powerful testament to the appeal of high-quality Test cricket and the elevated context of the WTC Final. This format continues to command a loyal and passionate global following and remains an integral part of our sport’s identity.

    “What makes this success even more special is the enthusiasm shown by fans in regions beyond the two competing nations, reaffirming that cricket’s reach is truly international, and that the purest form of the game can thrive beyond national affiliations.

    “A special mention to JioStar, whose innovative and immersive coverage, captured the drama, emotion, and atmosphere of the ‘Ultimate Test’ in a way that deeply resonated with audiences around the world.”

    Continue Reading

  • Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer

    Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer

    Gastric cancer cells: © LASZLO – stock.adobe.com

    First-line treatment with bemarituzumab plus chemotherapy (mFOLFOX6) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) vs placebo plus chemotherapy in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive, according to findings from the phase 3 FORTITUDE-101 trial (NCT05052801).1

    In the study, FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry testing. With this, the primary end point of the phase 3 FORTITUDE-101 trial (NCT05052801) was met at its prespecified interim analysis.

    Looking at safety, the most frequently reported treatment-emergent adverse events (TEAEs) occurring in more than 25% of patients receiving the bemarituzumab plus chemotherapy regimen included decreased visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelial defects, and dry eye. Ocular toxicities, which were consistent with findings from the phase 2 trial, occurred in both treatment arms but were notably more frequent and more severe in the bemarituzumab arm of the phase 3 study.

    Full results from the trial will be presented at a future medical meeting.

    “Most patients with gastric cancer are diagnosed at an advanced stage, with poor prognosis, low survival rates, and limited therapeutic options,” said Jay Bradner, MD, executive vice president of research and development at Amgen, in a press release. “These first positive topline results of an FGFR2b targeted monoclonal antibody from our phase 3 FORTITUDE-101 study mark a meaningful advance in the development of effective targeted therapy for gastric cancer.”

    The randomized, multicenter, double-blind, placebo-controlled, phase 3 FORTITUDE-101 trial evaluated bemarituzumab plus mFOLFOX6 vs placebo plus mFOLFOX6 as first-line therapy in 547 patients with advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial included 300 sites across 37 countries.

    Enrollment was open to patients with histologically documented unresectable, locally advanced/metastatic G/GEJ cancer not amenable to curative therapy who had FGFR2b overexpression. Patients were required to have an ECOG performance status of 1 or less; measurable disease or nonmeasurable but evaluable disease, according to RECIST v1.1; no contraindications to mFOLFOX6 chemotherapy; and adequate organ and bone marrow function.2

    The primary end point of the study is OS, and secondary end points include progression-free survival, overall response rate, number of patients who experience a TEAE, duration of response, disease control rate, pharmacokinetics.

    In addition to FORTITUDE-101, a phase 3 trial (NCT05111626) is currently evaluating bemarituzumab plus chemotherapy and nivolumab (Opdivo) in patients with first-line gastric cancer. Data from this study are expected to read out in the second half of 2025.

    REFERENCES:
    1. Amgen announces positive topline phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (FGFR2B) positive first-line gastric cancer. News release. Amgen. June 30, 2025. Accessed June 30, 2025. https://tinyurl.com/2vck8tjj
    2. Bemarituzumab or placebo plus chemotherapy in gastric cancers with fibroblast growth factor receptor 2b (FGFR2b) overexpression (FORTITUDE-101). News release. February 7, 2025. Accessed June 30, 2025. https://clinicaltrials.gov/study/NCT05052801

    Continue Reading

  • Suriname certified malaria-free by WHO

    Suriname certified malaria-free by WHO

    Today, Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO). This historic milestone follows nearly 70 years of commitment by the government and people of Suriname to eliminate the disease across its vast rainforests and diverse communities.

    “WHO congratulates Suriname on this remarkable achievement,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This certification is a powerful affirmation of the principle that everyone—regardless of nationality, background, or migration status—deserves universal access to malaria diagnosis and treatment. Suriname’s steadfast commitment to health equity serves as an inspiration to all countries striving for a malaria-free future.”

    With today’s announcement, a total of 46 countries and 1 territory have been certified as malaria-free by WHO, including 12 countries in the Region of the Americas.

    “Suriname did what was needed to eliminate malaria—detecting and treating every case quickly, investigating to prevent spread, and engaging communities,” said Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), WHO’s regional office for the Americas. “This certification reflects years of sustained effort, especially reaching remote areas. It means future generations can grow up free from this potentially deadly disease.”

    Certification of malaria elimination is granted by WHO when a country has proven, beyond reasonable doubt, that the chain of indigenous transmission has been interrupted nationwide for at least the previous three consecutive years.

    Dr Amar Ramadhin, Minister of Health of Suriname, stated: “Being malaria-free means that our population is no longer at risk from malaria. Furthermore, eliminating malaria will have positive effects on our healthcare sector, boost the economy, and enhance tourism.

    “At the same time, we recognize that maintaining this status requires ongoing vigilance. We must continue to take the necessary measures to prevent the reintroduction of malaria. We are proud that our communities are now protected, and we look forward to welcoming more visitors to our beautiful Suriname—while remaining fully committed to safeguarding these hard-won gains.”

    Suriname’s road to elimination

    Suriname’s malaria control efforts began in 1950s in the country’s densely-populated coastal areas, relying heavily on indoor spraying with the pesticide DDT and antimalarial treatment. By the 1960s, the coastal areas had become malaria-free and attention turned towards the country’s forested interior, home to diverse indigenous and tribal communities.

    Although indoor spraying was successful in coastal areas, its impact was limited in the country’s interior due to the prevalence of traditional open-style homes that offer minimal protection against mosquitoes. In 1974 malaria control in the interior was decentralized to Medische Zending, Suriname’s primary health care service, which recruited and trained healthcare workers from the local communities to provide early diagnosis and treatment.

    The surge in mining activities, particularly gold mining which often involves travel between malaria-endemic areas, led to increases in malaria, reaching a peak of more than 15 000 cases in 2001, the highest transmission rates of malaria in the Americas.

    Since 2005, with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria, the capacity to provide diagnosis was greatly expanded with both improvements in microscopy and the use of rapid diagnostic tests, particularly among mobile groups. Artemisinin-based treatments with primaquine were introduced in Suriname and neighboring countries through PAHO-led studies under the Amazon Malaria Initiative (AMI-RAVREDA), supported by the United States. Prevention among high-risk groups was also strengthened through the distribution of insecticide-treated nets funded by the Global Fund.

    By 2006, malaria had drastically decreased among the indigenous populations, prompting Suriname to shift its focus to high-risk mobile populations in remote mining areas. To reach these groups—many of whom were migrants from neighboring endemic countries—the country established a network of Malaria Service Deliverers, recruited directly from the mining communities. These trained and supervised community workers provide free malaria diagnosis, treatment, and prevention services, playing a vital role in closing access gaps in hard-to-reach regions.

    Through ensuring universal access to diagnosis and treatment regardless of legal status, deploying an extensive network of community health workers, and implementing nationwide malaria screening, including at border crossings, Suriname successfully eliminated malaria. The last locally transmitted case of Plasmodium falciparum malaria was recorded in 2018, followed by the final Plasmodium vivax case in 2021.

    Sustained leadership commitment and funding

    The government of Suriname has shown strong commitment to malaria elimination, including through the National Malaria Elimination Taskforce, Malaria Program, Malaria Elimination Fund, and cross-border collaboration with Brazil, Guyana and French Guiana. For many years PAHO/WHO, with the support of the U.S. Government, has provided technical cooperation throughout Suriname’s anti-malaria campaign. Since 2016 Suriname also participated in the “Elimination 2025” initiative – a group of countries identified by WHO as having the potential to eliminate malaria by 2025.

    This success in Suriname is a demonstration that malaria elimination is possible in challenging contexts in the Amazon basin and in tropical continental countries. The country’s malaria-free certification plays a critical role in advancing PAHO’s Disease Elimination Initiative which aims to eliminate more than 30 communicable diseases, including malaria, in countries of the Americas by 2030.

    Note to the editor

    WHO malaria-free certification

    The final decision on awarding a malaria-free certification is made by the WHO Director-General, based on a recommendation by the Technical Advisory Group on Malaria Elimination and Certification and validation from the Malaria Policy Advisory Group. For more on WHO’s malaria-free certification process, visit  this link.

     

    Continue Reading

  • VALORANT Season 2025 Act 4 – new Corrode map explained – Esports Insider

    1. VALORANT Season 2025 Act 4 – new Corrode map explained  Esports Insider
    2. VALORANT 11.00 Patch Notes: Act 4 Release Time, New Map, Huge Duelist Changes  Sports Illustrated
    3. VALORANT’s New Map Corrode Sparks Heated Debate Among Players  happygamer.com
    4. Valorant geht mit großem Update heute weiter – Patch Notes  Mein-MMO
    5. Riot Reveals New Valorant Map ‘Corrode’ – Launching In A Few Days  GameTyrant

    Continue Reading

  • Tiny Nose Robots Developed to Clear Sinus Infections – AI Business

    1. Tiny Nose Robots Developed to Clear Sinus Infections  AI Business
    2. Swarms of tiny nose robots could clear infected sinuses, researchers say  The Guardian
    3. Swarms of tiny ‘nose robots’ clear out sinuses  New Atlas
    4. Light-powered robot swarms may replace antibiotics for tough sinus infections  Yahoo
    5. Swarms of tiny robots could go up your nose, melt the mucus and clean your sinuses  ZME Science

    Continue Reading

  • MacBook Air 2025 deal: Save $150 on all colorways

    MacBook Air 2025 deal: Save $150 on all colorways

    GET $150 OFF: As of June 30th, all colors of the Apple MacBook Air 2025 (M4 Chip, 16GB RAM, 256GB SSD) are on sale for $849, down from their regular price of $999, for a savings of 15%, or $150 off.


    We already got excited about Apple’s 2025 MacBook Air hitting $150 off ahead of Prime Day, but last week you could only get one color: Starlight. Now we’re doubly hyped, with all colorways going on sale for the same 15% price cut… Yes, that includes Sky Blue, classic Silver, and Midnight. The choice is yours.

    Right now, all colorways of Apple’s 2025 MacBook Air (M4 Chip, 16GB RAM, 256GB SSD) are on sale for $849, saving you $150.

    SEE ALSO:

    The best laptops for 2025: Tested for performance, battery life, design, and value

    The best laptop deals we’re watching right now

    The new Macbook Airs incorporate Apple’s supercharged M4 Chip, which are supported by 16GB of RAM. Even with a remarkably thin profile, these computers churn through calculations, so whether you’re running scientific experiments, performing, gaming, or simply opening lots of tabs, you’ll have the power you need.

    Beyond computing power, the 2025 Air has a Retina display with 1 billion colors and a 12MP camera. It will support you in graphic design projects and online meetings.

    Mashable Deals

    Grab this deal to get any color of Apple’s 2025 Macbook Air (M4 Chip, 16GB RAM, 256GB SSD) for $150 off, and pay $849.

    Built as the portable option among Apple’s laptops, the Air manages to fit an impressive battery in its half-inch thick body, and holds a charge for up to 18 hours. With such good battery life, it’s an excellent around-town laptop.

    Continue Reading

  • Intermittent energy restriction may improve outcomes in people with obesity and type 2 diabetes

    Intermittent energy restriction may improve outcomes in people with obesity and type 2 diabetes

    Intermittent energy restriction, time-restricted eating and continuous energy restriction can all improve blood sugar levels and body weight in people with obesity and type 2 diabetes, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

    “This study is the first to compare the effects of three different dietary interventions intermittent energy restriction (IER), time-restricted eating (TRE) and continuous energy restriction (CER) in managing type 2 diabetes with obesity,” said Haohao Zhang, Ph.D., chief physician at The First Affiliated Hospital of Zhengzhou University in Zhengzhou, China.

    Although researchers identified improved HbA1c levels, and adverse events were similar across the three groups, the IER group showed greater advantages in reducing fasting blood glucose, improving insulin sensitivity, lowering triglycerides, and strengthening adherence to the dietary interventions.

    “The research fills a gap in directly comparing 5:2 intermittent energy restriction with a 10-hour time-restricted eating in patients with obesity and type 2 diabetes. The findings provide scientific evidence for clinicians to choose appropriate dietary strategies when treating such patients,” Zhang said.

    Zhang and colleagues performed a single-center, randomized, parallel-controlled trial at the First Affiliated Hospital of Zhengzhou University from November 19, 2021 to November 7, 2024.

    Ninety patients were randomly assigned in a 1:1:1 ratio to the IER, TRE or CER group, with consistent weekly caloric intake across all groups. A team of nutritionists supervised the 16-week intervention.

    Of those enrolled, 63 completed the study. There were 18 females and 45 males, with an average age of 36.8 years, a mean diabetes duration of 1.5 years, a baseline BMI of 31.7 kg/m², and an HbA1c of 7.42%. 

    At the end of the study, there were no significant differences in HbA1c reduction and weight loss between the IER, TRE and CER groups. However, the absolute decrease in HbA1c and body weight was greatest in the IER group. 

    Compared to TRE and CER, IER significantly reduced fasting blood glucose and triglycerides and increased the Matsuda index, a measure of whole-body insulin sensitivity. Uric acid and liver enzyme levels exhibited no statistically significant changes from baseline in any study group.

    Two patients in the IER group and the TRE group, and three patients in the CER group, experienced mild hypoglycemia. 

    The IER group had the highest adherence rate (85%), followed by the CER group at 84% and the TRE group at 78%. Both the IER and CER groups showed statistically significant differences compared with the TRE group.

    Zhang said these findings highlight the feasibility and effectiveness of dietary interventions for people who have obesity and type 2 diabetes.

    About Endocrine Society
    Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

    The Society has more than 18,000 members, including scientists, physicians, educators, nurses, and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on X (formerly Twitter) at @TheEndoSociety and @EndoMedia.


    Continue Reading